Authors : Naei VY; School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, Australia.; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

Subjects: B7-H1 Antigen*/B7-H1 Antigen*/B7-H1 Antigen*/metabolism ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/immunology ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/pathology

Source: Journal of translational medicine [J Transl Med] 2025 Feb 12; Vol. 23 (1), pp. 177. Date of Electronic Publication: 2025 Feb 12.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells.

Authors : Li G; Department of Radiology, Yan'an Hospital of Kunming City (Yan'an Hospital Affiliated to Kunming Medical University, Yunnan Cardiovascular Hospital), Kunming, China.; Yang H

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/immunology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/therapy

Source: Journal of translational medicine [J Transl Med] 2025 Feb 07; Vol. 23 (1), pp. 164. Date of Electronic Publication: 2025 Feb 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma.

Authors : Gao Y; School of Public Health and Health Management, Gannan Medical University, Ganzhou, 341000, China.; Huo Y

Subjects: Melanoma*/Melanoma*/Melanoma*/drug therapy ; Melanoma*/Melanoma*/Melanoma*/immunology ; Melanoma*/Melanoma*/Melanoma*/genetics

Source: Scientific reports [Sci Rep] 2025 Mar 25; Vol. 15 (1), pp. 10235. Date of Electronic Publication: 2025 Mar 25.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.

Authors : Lan H; Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, No. 56 Haier Road, Qingdao, 266000, Shandong, China.; Zhu J

Subjects: Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/pathology ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/immunology

Source: Cell communication and signaling : CCS [Cell Commun Signal] 2025 Mar 14; Vol. 23 (1), pp. 137. Date of Electronic Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-811X

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy.

Authors : Yen YT; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.; Zhang Z

Subjects: Programmed Cell Death 1 Receptor* ; Transforming Growth Factor beta*/Transforming Growth Factor beta*/Transforming Growth Factor beta*/metabolism ; Nanoparticles*/Nanoparticles*/Nanoparticles*/chemistry

Source: Journal of nanobiotechnology [J Nanobiotechnology] 2025 Feb 19; Vol. 23 (1), pp. 124. Date of Electronic Publication: 2025 Feb 19.Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Assessment of Programmed Cell Death Protein 1 and Programmed Cell Death Ligand 1 Expression in Gestational Trophoblastic Neoplasia: Implications for Anti-PD1 Drug Therapy.

Authors : Farazestanian, Marjane¹; Hasani, Fatemeh²; Norouzi, Zahra²

Subjects: *THERAPEUTIC use of monoclonal antibodies; *CROSS-sectional method; *PROGRAMMED death-ligand 1IRAN

Source: Journal of Obstetrics, Gynecology & Cancer Research. Feb2025, Vol. 10 Issue 2, p94-101. 8p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.

Authors : Sun Q; State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.; Hong S

Subjects: Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/antagonists & inhibitors ; Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/metabolism ; Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/Programmed Cell Death 1 Receptor*/immunology

Source: International journal of molecular sciences [Int J Mol Sci] 2025 Jan 31; Vol. 26 (3). Date of Electronic Publication: 2025 Jan 31.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4.

Authors : Liu Z; Department of Colorectal and Anal Surgery, The Second Hospital of Jilin University, Changchun, Jilin, 130000, China.; Chu H

Subjects: CTLA-4 Antigen*/CTLA-4 Antigen*/CTLA-4 Antigen*/immunology ; CTLA-4 Antigen*/CTLA-4 Antigen*/CTLA-4 Antigen*/antagonists & inhibitors ; Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/immunology

Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2025 Jan; Vol. 12 (3), pp. e2408899. Date of Electronic Publication: 2024 Nov 28.Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).

Authors : Wu J; Department of Neurosurgery, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China.; Wang N

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/therapy ; Glioblastoma*/Glioblastoma*/Glioblastoma*/immunology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/drug therapy

Source: Molecular medicine reports [Mol Med Rep] 2024 Dec; Vol. 30 (6). Date of Electronic Publication: 2024 Oct 04.Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy.

Authors : Cotra S; Department of Applied Mathematics, University of Waterloo, Waterloo, ON N2L 3G1, Canada.; Kohandel M

Subjects: Immunotherapy* ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/pharmacology ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use

Source: Biomolecules [Biomolecules] 2024 Nov 27; Vol. 14 (12). Date of Electronic Publication: 2024 Nov 27.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response.

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells.

Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma.

Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.

Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy.

Assessment of Programmed Cell Death Protein 1 and Programmed Cell Death Ligand 1 Expression in Gestational Trophoblastic Neoplasia: Implications for Anti-PD1 Drug Therapy.

Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.

Polymeric Multivalent Fc Binding Peptides-Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA-4.

Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy.

اتصل بنا

اتبع